Equities Analysts Set Expectations for IONS FY2028 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Stock analysts at William Blair decreased their FY2028 earnings estimates for Ionis Pharmaceuticals in a research report issued to clients and investors on Friday, December 20th. William Blair analyst M. Minter now forecasts that the company will post earnings of $2.07 per share for the year, down from their previous estimate of $2.26. William Blair has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.37) per share.

A number of other research firms also recently commented on IONS. Wells Fargo & Company decreased their target price on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Piper Sandler decreased their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, StockNews.com cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $60.65.

Ionis Pharmaceuticals Stock Up 1.3 %

NASDAQ IONS opened at $36.08 on Monday. The company has a current ratio of 8.91, a quick ratio of 8.82 and a debt-to-equity ratio of 1.86. The stock’s 50 day moving average is $37.33 and its 200 day moving average is $42.26. Ionis Pharmaceuticals has a 12 month low of $33.33 and a 12 month high of $54.44. The stock has a market cap of $5.70 billion, a PE ratio of -14.79 and a beta of 0.35.

Insiders Place Their Bets

In other news, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the transaction, the executive vice president now directly owns 33,713 shares of the company’s stock, valued at $1,278,396.96. This represents a 3.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at approximately $6,369,303.65. The trade was a 3.81 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,877 shares of company stock worth $299,578. Corporate insiders own 2.71% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Several large investors have recently bought and sold shares of IONS. Vanguard Personalized Indexing Management LLC raised its stake in Ionis Pharmaceuticals by 3.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after purchasing an additional 261 shares during the period. Nicollet Investment Management Inc. raised its holdings in Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock valued at $817,000 after buying an additional 294 shares during the period. Amalgamated Bank lifted its position in Ionis Pharmaceuticals by 3.1% in the third quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after buying an additional 300 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after acquiring an additional 303 shares during the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Ionis Pharmaceuticals by 40.9% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after acquiring an additional 314 shares during the period. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.